Selinexor Clinical Trials
28 recruitingDrug
Phase 220Phase 112Phase 34Not Applicable1
Showing 1–20 of 28 trials
Recruiting
Phase 2
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
Metastatic Alveolar Soft Part SarcomaAdvanced Soft Tissue SarcomaAdvanced Alveolar Soft Part Sarcoma+2 more
National Cancer Institute (NCI)27 enrolled13 locationsNCT05333458
Recruiting
Phase 1Phase 2
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Malignant Glioma
National Cancer Institute (NCI)132 enrolled127 locationsNCT05099003
Recruiting
Phase 1
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Multiple Myeloma
Washington University School of Medicine20 enrolled1 locationNCT07200102
Recruiting
Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie380 enrolled166 locationsNCT06158841
Recruiting
Phase 3
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.228 enrolled1 locationNCT07138209
Recruiting
Phase 2
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
University of Miami33 enrolled3 locationsNCT05530421
Recruiting
Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931
Recruiting
Phase 2
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Multiple Myeloma, Refractory
Karyopharm Therapeutics Inc127 enrolled16 locationsNCT04414475
Recruiting
Phase 1Phase 2
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting
Phase 1Phase 2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Multiple Myeloma
Karyopharm Therapeutics Inc300 enrolled25 locationsNCT02343042
Recruiting
Phase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled15 locationsNCT05985161
Recruiting
Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc244 enrolled176 locationsNCT02227251
Recruiting
Phase 1Phase 2
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Central Nervous System Lymphoma
Tong Chen, MD30 enrolled5 locationsNCT05698147
Recruiting
Phase 2
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University35 enrolled6 locationsNCT05900882
Recruiting
Phase 1Phase 2
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT06556199
Recruiting
Phase 1Phase 2
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Advanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers
National University Hospital, Singapore63 enrolled1 locationNCT05035745
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
Natural Killer/T-cell LymphomaRelapsed or Refractory Lymphoma Including ENKL
Fudan University68 enrolled1 locationNCT06966154
Recruiting
Not Applicable
Second-line Immunotherapy for ES-SCLC
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06853678
Recruiting
Phase 2
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
University of Rochester15 enrolled1 locationNCT05597345
Recruiting
Phase 1
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics30 enrolled1 locationNCT06225310